Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Cash & Current Investments for 7 consecutive years, with $170.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 82.84% year-over-year to $170.4 million; the TTM figure through Mar 2026 stood at $170.4 million (up 82.84% YoY), while the FY2025 annual figure was $178.8 million, up 83.27% from the prior year.
• Cash & Current Investments eased to $170.4 million in Q1 2026 per IKT's latest filing, from $178.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $178.8 million in Q4 2025 and bottomed at $3.2 million in Q3 2024.
• Historically, Cash & Current Investments has averaged $54.2 million across 5 years, with a median of $26.5 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 80.73% — and 2025, when it jumped 2283.81%.
• Inhibikase Therapeutics' Cash & Current Investments stood at $23.1 million in 2022, then tumbled by 42.51% to $13.3 million in 2023, then jumped by 636.06% to $97.5 million in 2024, then surged by 83.27% to $178.8 million in 2025, then decreased by 4.7% to $170.4 million in 2026.
• Business Quant data shows IKT's Cash & Current Investments at $170.4 million in Q1 2026, $178.8 million in Q4 2025, and $77.3 million in Q3 2025.